Table 1 Study inclusion criteria

Histopathological confirmation of prostate cancer

Indication of Gleason score and the highest value of prostate-specific antigen (PSA) concentration

Clinical stage assessment according to the TNM classification

No distant metastases (M0) confirmed based on abdominal ultrasound/CT, chest X-ray/CT and scintigraphy

No other concurrent or previous cancer (excepting skin cancer, with at least a 5-year disease free follow-up)

Radiotherapy as a definitive treatment method, using uniform contouring criteria of treatment volumes and critical structures; 3D or dynamic techniques; image guided radiotherapy (IGRT)

Regular (weekly during treatment and on every visit during follow-up) evaluation of acute and late toxicity from the gastrointestinal and genitourinary tracts, based on the EORTC/RTOG criteria